Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK4418959 (WRN inhibitor) in dMMR/MSI-H solid tumors
NCT06710847Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of GSK4418959 in colorectal cancer (CRC), endometrial cancer (EC) and solid tumor (3 arms), sponsored by GSK. Primary endpoints: Dose Limiting Toxicities at 21 days, Treatment Emergent Adverse Events during DLT observation period at 21 days and 2 more. Started Dec 2024; status: active, not recruiting.
02
Drugs
GSK4418959
03
Conditions
colorectal cancer (CRC)endometrial cancer (EC)solid tumor
Beyond the preview
Go deeper on NCT06710847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06710847.